Epochal is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease
Coronary Artery Disease and Coronary Microvascular Dysfunction Are More Common in Patients With Heart Failure Who Have a Preserved Ejection Fraction.
https://t.co/BPiML23NmB
The ECC Foundation has participated in investing in a cell NFT project called "Future", which uses preferential subsidies to complete the vision of stem cell therapy globalization
ECC Foundation established! This is a key step in our global strategic landscape, and ECC will become a road that Epochal can extend beyond the circle.
🐯新春快乐
Happy Chinese New Year to my Chinese friends!
We wish everyone health, happiness and all the best in 2022,we all focus on getting better in the new year by ECC
#ChineseNewYear